Evaluation of Blood Inhibin-A Level in Pregnant Women on Pregnancy Outcome in Mothers Referred to Educational Hospitals in Isfahan City in 2021-2022

Document Type : Original Article(s)

Authors

1 Associate Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i837.1440

Abstract

Background: This study aimed to investigate the relationship between serum inhibin A levels in pregnant mothers and pregnancy outcomes in mothers referred to teaching hospitals in Isfahan in 2021-2022.
Methods: This cross-sectional study was conducted among pregnant women at educational hospitals in Isfahan Province between March 2021 and March 2022. A total of 121 singleton pregnant women who underwent the second trimester quad screen test were included. Serum samples were collected and analyzed for inhibin A levels, which were expressed as multiples of the median. Adverse pregnancy outcomes, including preeclampsia, gestational diabetes mellitus (GDM), and neonatal complications, were assessed.
Findings: Overall, 121 pregnant women with a mean age of 31.5 ± 4.9 years were enrolled. Statistically significant correlations were observed between elevated maternal serum inhibin A levels and adverse pregnancy outcomes. Notably, high inhibin A levels were associated with an increased incidence of preeclampsia (P < 0.001), neonatal intensive care unit (NICU) admission (P < 0.001), lower Apgar scores (P = 0.018), and intrauterine growth restriction (IUGR) (P = 0.013).
Conclusion: Our findings suggest that maternal serum inhibin A level is a valuable predictor of adverse pregnancy outcomes.

Highlights

Minoo Movahedi: Google Scholar 

Maryam Mohammadi: Google Scholar

Keywords

Main Subjects

References

  1. Ando H. Inhibin. Handbook of Hormones. Boston, MA: Elsevier; 2021.   555-8..
  2. . Welt C, Schneyer A. Inhibin, activin, and follistatin in ovarian physiology. The Ovary (Third Edition) 2019; 95-105.
  3. Dinc K, Ozyurt R, Sık BA, Kumbasar S, Akpak YK, Aba YA. Effects of secondary trimester maternal serum screening on the results of pregnancy. J Hum Sci 2017; 14(4): 3653-62.
  4. Faraji A. High level serum Inhibin-A in 1st and 2th pregnancy trimesters as a risk factor for adverse pregnancy outcomes: a systematic review and meta-analysis.. PJMS 2022; 18(4): 25-34.
  5. . Yue C-Y, Zhang C-Y, Ni Y-H, Ying C-M. Are serum levels of inhibin A in second trimester predictors of adverse pregnancy outcome.? PLoS One 2020; 15(5): e0232634.
  6. Raczkowska BA, Zbucka-Kretowska M, Kretowski A, Ciborowski M. Biomarkers of abnormal birth weight in pregnancy. Nutrients 2017: 503-16.
  7. Ozgen G, Aydin GA. The predictive value of maternal serum screening tests for adverse pregnancy outcomes . Ann Med Res 2020; 27(4): 1268-74.
  8. Huang S-Y, Wang Y-C, Yin W-C, Teng L-F, Huang Y-C, Wu Y-L, et al. Is maternal serum inhibin A a good predictor in preterm labor?-Experience from a community hospital in Taiwan. . Biomed J 2020; 43(2): 183-8.
  9. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, et al. Quad screen as a predictor of adverse pregnancy outcome. . Obstet Gynecol 2005; 106(2): 260-7.
  10. Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH. Prediction of spontaneous preterm delivery from maternal factors, obstetric historyand placental perfusion and function at 11–13 weeks. Prenat Diagn 2011; 31(1): 75-83.
  11. Singnoi W, Wanapirak C, Sekararithi R, Tongsong T. A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study. . BMC Pregnancy Childbirth 2019; 19(1): 124.
  12. Florio P, Cobellis L, Luisi S, Ciarmela P, Severi F, Bocchi C, et al. Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol 2001; 180(1-2): 123-30.
  13. Sehat Z, Goshetasbi A, Amin MT. Investigating association between second trimester maternal serum biomarkers and pre-term delivery. Iran J Reprod Med 2013; 11(2): 127-32.
  14. Neuman RI, Alblas van der Meer MM, Nieboer D, Saleh L, Verdonk K, Kalra B, et al. PAPP‐A2 and inhibin a as novel predictors for pregnancy . J Am Heart Assoc 2020; 9(19): e018219.
  15. Tal R, Taylor HS. Endocrinology of pregnanc In: Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.
  16. Von Dadelszen P, Magee LA. Preventing deaths due to the hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2016: 36: 83-102.
  17. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020 2020; 43(Suppl 1): S14-S31.
  18. .Khedr AH, Soliman ASM, Amrousy YM, Belal SE Role of Progesterone and Inhibin A in Predicting the Adverse Outcome of Pregnancy. Journal of Medicine in Scientific Research 2024; 7(2).
  19. Alizadeh-Dibazari Z, Alizadeh-Ghodsi Z, Fathnezhad-Kazemi A. Association Between Serum Markers Used in the Routine Prenatal Screening with Pregnancy Outcomes: A Cohort Study. J Obstet Gynaecol India 2022; 72(Suppl 1): 6-18.
  20. D'Anna R, Baviera G, Corrado F, Leonardi I, Buemi M, Jasonni V. Is mid-trimester maternal serum inhibin-A a marker of preeclampsia or intrauterine growth restriction? Acta Obstet Gynecol Scand 2002; 81(6): 540-3.
  21. Tul N, Pušenjak S, Osredkar J, Spencer K, Novak‐Antolič Ž. Predicting complications of pregnancy with first‐trimester maternal serum free‐βhCG, PAPP‐A and inhibin‐A. Prenat Diagn 2003; 23(12): 990-6.
Journal of Isfahan Medical School
Volume 43, Issue 837
1st Week, January
January and February 2026
Pages 1440-1446

Files

History

  • Receive Date: 11 January 2025
  • Accept Date: 25 August 2025

Share

How to cite

Statistics